Eukarÿs SAS

📍 Évry, France🗓 Founded 2010👥 2 employees💰 Last funded May 2009
Biotechnology🌐 eukarys.com
Website LinkedIn
Eukarÿs has developed the first ever artificial expression system able to synthesize in vivo autonomously messenger RNA (mRNA) and consequently the protein of interest in mammalian and other eukaryotic cells. Using the C3P3 system, Eukarÿs develop the unique synthetic gene therapy approach, which is a non-viral, safe, non-integrative, efficient, cost-effective, well-tolerated approach to treat human monogenic and multifactorial disorders. The same C3P3 system is also used for synthetic gene vaccination. For further information, see www.eukarys.com.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2010
Founded

Investors

1 investor
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in Eukarÿs SAS?
Eukarÿs SAS has 1 investor on record on gritt.io, including 1 early-stage backers.
When did Eukarÿs SAS last raise funding?
The most recent investment in Eukarÿs SAS recorded on gritt.io was in May 2009.
When was Eukarÿs SAS founded?
Eukarÿs SAS was founded in 2010.
What industry is Eukarÿs SAS in?
Eukarÿs SAS operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Eukarÿs SAS based?
Eukarÿs SAS is headquartered in Évry, France.